Archer pushes Biochip into beta phase, eyes clinical validation and scale-up

Archer Materials ( (AU:AXE) ) has provided an update.

Archer Materials has moved its Biochip program from an alpha prototype to the development of a beta prototype designed for external use and pre-clinical validation. The system will integrate a silicon-based sensing chip with Archer’s proprietary functionalisation, cartridge engineering, microfluidics, and readout electronics to enable potassium testing and support future diagnostic applications.

The company has chosen silicon for current prototypes to accelerate development and tap into established manufacturing pathways, while keeping graphene as a next-generation platform for performance upgrades and product expansion. Management stresses that the core value lies in its functionalised sensing layer, surface chemistry, and signal processing architecture, which can be applied across different chip substrates, reducing manufacturing risk and aiding commercialisation.

Next steps focus on engineering a user-ready cartridge, integrating electronics and software, and running stability and usability testing to prepare the device for external laboratories and clinical workflows. Archer is also progressing Stage 2 discussions with IMEC to support fabrication scale-up, packaging, and clinical trial preparation, positioning the Biochip closer to regulatory pathways and eventual market launch.

The most recent analyst rating on (AU:AXE) stock is a Sell with a A$0.28 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.

More about Archer Materials

Archer Materials Limited is an Australian quantum technology company focused on developing advanced solutions in computing, sensing, and medical diagnostics. The company is building proprietary biochip platforms that leverage semiconductor fabrication and specialised surface chemistry to target clinical testing applications, initially centred on potassium sensing with potential expansion to broader diagnostic use cases.

Average Trading Volume: 210,867

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$73.91M

For detailed information about AXE stock, go to TipRanks’ Stock Analysis page.